Tag: AAV

January 20, 2023

Forge Biologics, a gene therapy-focused contract development and manufacturing organization (CDMO), said that the European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to FBX-101, Forge’s lead adeno-associated virus (AAV) drug candidate and novel gene therapy for treating patients […]

August 26, 2022

The US biotech claimed conditional marketing approval from the European Commission for Roctavian (valoctocogene roxaparvovec) as a treatment for adults with severe haemophilia A, who don’t have a history of developing the antibodies that inhibit the activity of blood-clotting protein […]

May 16, 2022

Catalent, a company enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, has introduced its new, UpTempo Virtuoso platform process for the development and CGMP manufacturing of adeno-associated […]

April 13, 2022

VectorBuilder, a global gene delivery solutions company, announced on April 11, 2022 the construction of a new $500 million R&D and manufacturing center in Guangzhou, China. The ‘Gene Delivery Research and Manufacturing Campus’ will aid in the growth of the […]

January 28, 2022

Homology Medicines has found a source of fresh funding. With its share price in the doldrums and its cash runway nearing its final year, Homology is offloading manufacturing assets through a joint venture to raise $130 million for clinical development […]

December 6, 2021

Astellas Pharma and Dyno Therapeutics have announced an option and license agreement to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno’s CapsidMap™ platform. Dyno’s CapsidMap platform represents a new approach applying […]

October 8, 2021

Researchers show combining mass spectrometry and a gas-phase electrophoretic mobility molecular analyser improves detection of full and empty virus-like particles for gene therapies. Adeno-associated viruses (AAV) are the leading virus-like particle (VLP) vehicles for gene therapies, but how can AAVs […]

October 6, 2021

Pfizer is paying Voyager $30 million upfront to get access to its TRACER adeno-associated virus (AAV) vector technology, which aims to improve the safety of gene therapies – a field that has suffered a string of safety scares in the […]

September 22, 2021

Novartis have announced that it has acquired Arctos Medical, adding a pre-clinical optogenetics-based Adeno-associated viruses (AAV) gene therapy programme and Arctos’ proprietary technology to its ophthalmology portfolio. The acquisition aims to more efficiently develop treatments for patients with vision loss […]

August 9, 2021

The biopharmaceutical market, one of the fastest growing segments in the life sciences industry, is valued at approximately USD 325.17 billion in 2020(1). The segment is expected to continue its upward trajectory at a compound aggregate growth rate of 7.32% […]

May 21, 2021

VectorY was chosen for its development of proprietary and partnered programs based on a novel adeno-associated viruses (AAV) platform for the treatment of muscular and neurodegenerative disorders. The company currently has a pipeline of vectorized antibodies, including two in pre-clinical […]

April 29, 2021

Gene therapy-focused CDMO Forge Biologics has closed on a $120 million Series B financing, saying the proceeds will accelerate its planned expansion of adeno-associated virus (AAV) manufacturing capabilities. The company operates a 175,000-square-foot cGMP facility in Columbus, OH, dedicated to […]

February 11, 2021

As part of the agreement, Rentschler will invest in the site over the next five years to bolster their manufacturing capabilities. This investment is expected to make a ‘major contribution’ to creating suitable manufacturing capability for cell and gene therapies, […]

May 1, 2020

Cevec Pharmaceuticals announced the launch of the ELEVECTA platform, a technology that enables the large-scale manufacture of adeno-associated virus (AAV) vectors by producing fully stable producer cell lines. The technology is paten protected and is now commercially available for gene […]